Information Provided By: 
Fly News Breaks for May 6, 2019
IMGN
May 6, 2019 | 09:16 EDT
Cowen analyst Boris Peaker upgraded ImmunoGen to Outperform from Market Perform, saying the company noted on its Q1 earnings conference call that all secondary endpoints continued to trend positively in FRa high patients from the FORWARD I trial. Peaker tells investors in a research note that he sees additional clarity in the second half of the year after the company meets with the FDA, and says he believes shares are undervalued. If approved, Peaker says he believes that ImmunoGen's drug could acheive peak sales of ~1.6B per year.
News For IMGN From the Last 2 Days
There are no results for your query IMGN
